Equities Analysts Offer Predictions for ONCY FY2024 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Equities research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a note issued to investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.28) per share for the year, up from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q1 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.41 EPS.

Other equities research analysts also recently issued research reports about the stock. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th. Leede Financial lowered shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th.

Oncolytics Biotech Trading Up 3.3 %

ONCY opened at $0.74 on Wednesday. The stock’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $0.97. The stock has a market cap of $59.26 million, a PE ratio of -2.74 and a beta of 1.24. Oncolytics Biotech has a 1 year low of $0.67 and a 1 year high of $1.53.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Vantage Point Financial LLC purchased a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 29,744 shares of the company’s stock, valued at approximately $27,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.